Pyruvate dehydrogenase kinase

About: Pyruvate dehydrogenase kinase is a research topic. Over the lifetime, 4224 publications have been published within this topic receiving 161052 citations. The topic is also known as: [pyruvate dehydrogenase (lipoamide)] kinase & pyruvate dehydrogenase (lipoamide) kinase.

Metabolic control of hepatic gluconeogenesis during exercise.

Abstract: Prolonged exercise increased the concentrations of the hexose phosphates and phosphoenolpyruvate and depressed those of fructose 1,6-bisphosphate, triose phosphates and pyruvate in the liver of the rat. Since exercise increases gluconeogenic flux, these changes in metabolite concentrations suggest that metabolic control is exerted, at least, at the fructose 6-phosphate/fructose 1,6-bisphosphate and phosphoenolpyruvate/pyruvate substrate cycles. Exercise increased the maximal activities of glucose 6-phosphatase, fructose 1,6-bisphosphatase, pyruvate kinase and pyruvate carboxylase in the liver, but there were no changes in those of glucokinase, 6-phosphofructokinase and phosphoenolpyruvate carboxykinase. Exercise changed the concentrations of several allosteric effectors of the glycolytic or gluconeogenic enzymes in liver; the concentrations of acetyl-CoA, ADP and AMP were increased, whereas those of ATP, fructose 1,6-bisphosphate and fructose 2,6-bisphosphate were decreased. The effect of exercise on the phosphorylation-dephosphorylation state of pyruvate kinase was investigated by measuring the activities under conditions of saturating and subsaturating concentrations of substrate. The submaximal activity of pyruvate kinase (0.5 mM-phosphoenolpyruvate), expressed as percentage of Vmax., decreased in the exercised animals to less than half that found in the controls. These changes suggest that hepatic pyruvate kinase is less active during exercise, possibly owing to phosphorylation of the enzyme, and this may play a role in increasing the rate of gluconeogenesis.

Pyruvate kinase from the mantle tissue of (itMytilus Edulis) L.

Abstract: 1. 1. Mantle pyruvate kinase (E.C.2.7.1.40) is subject toa allosteric regulation, being inhibited by l -alanine and ATP and activated by fructose- 1,6-diphosphate (FDP). 2. 2. Substrate dependence of the enzyme is sigmoidal, and the sigmoidicity is increased at low pH. 3. 3. FDP at physiological concentrations overrides inhibition of the enzyme by l -alanine. 4. 4. The result of these modulators acting together suggests that both the reaction catalysed by pyruvate kinase (PEP → pyruvate) and the reaction catalysed by phosphoenolpyruvate carboxykinase (PEP → oxoloacetate) could proceed together, with the predominancer of one reaction over the other being determined by the degree of tissue hypoxia. 5. 5. The seasonal changes in the enzyme-substrate affinity are consistent with the known seasonal glycolytic and gluconeogenic sequence in the mantle.

Small-molecule targeting of the mitochondrial compartment with an endogenously cleaved reversible tag.

Abstract: Targeted accumulation of chemically unaltered compounds within the mitochondrial compartment has not yet been achieved. Here we describe a reversible tag that is endogenously cleaved after mitochondrial accumulation has occurred. Specifically, we have reversibly tagged alpha-lipoic acid with a triphenylphosphonium moiety that is cleaved by the physiologically contained mitochondrial aldehyde dehydrogenase (ALDH-2). This reversibly tagged compound activates the lipoic acid-sensitive pyruvate dehydrogenase complex, and this results in increased glucose oxidation. We observed a reduction in ROS accumulation after preincubation with the reversibly tagged compound, whereas untagged or irreversibly tagged compounds either had no effect on ROS formation or rather caused increased oxidative stress, respectively. Lastly, the cytotoxicity of the reversibly tagged compound is less than that of the irreversibly tagged compound. Overall, reversible tagging combines decreased tag-related cytotoxicity with increased bioactivity, and this potentially provides a novel concept in mitochondrial pharmacology.